Table 2. Age-adjusted incidence rates of potentially HPV-associated and non HPV-associated HNC for males and females by age and stagea, 1995–2005.
| Age-adjusted Incidence Rates (95% CI) | |||||||
| HPV-Associated Sites | Non HPV-Associated Sites | ||||||
| Category | Sub-Category | Total | Male | Female | Total | Male | Female |
| Age (Years) | 0–44 | 0.36 (0.35–0.37) | 0.56 (0.55–0.58) | 0.16 (0.15–0.17) | 0.72 (0.70–0.73) | 0.98 (0.96–1.00) | 0.45 (0.44–0.47) |
| 45–54 | 5.91 (5.83–6.00) | 10.14 (9.98–10.30) | 1.85 (1.78–1.91) | 10.57 (10.46–10.68) | 16.52 (16.32–16.73) | 4.84 (4.73–4.95) | |
| 55–64 | 9.73 (9.60–9.87) | 16.35 (16.10–16.60) | 3.64 (3.52–3.75) | 25.86 (25.64–26.07) | 41.07 (40.68–41.47) | 11.85 (11.65–12.06) | |
| 65+ | 7.94 (7.84–8.04) | 12.90 (12.71–13.10 | 4.21 (4.11–4.30) | 34.91 (34.70–35.12) | 57.15 (56.73–57.57) | 18.71 (18.51–18.91) | |
| Stage | Localized | 0.46 (0.46–0.47) | 0.71 (0.69–0.73) | 0.25 (0.24–0.26) | 4.21 (4.18–4.24) | 6.84 (6.79–6.89) | 2.10 (2.07–2.12) |
| Regional | 1.90 (1.88–1.92) | 3.21 (3.17–3.24) | 0.74 (0.72–0.75) | 2.94 (2.92–2.96) | 4.56 (4.52–4.60) | 1.56 (1.53–1.58) | |
| Distant | 0.35 (0.34–0.35) | 0.59 (0.58–0.61) | 0.13 (0.12–0.14) | 0.77 (0.76–0.78) | 1.27 (1.25–1.29) | 0.36 (0.35–0.37) | |
| Unstaged | 0.17 (0.17–0.18) | 0.28 (0.27–0.29) | 0.08 (0.07–0.08) | 0.64 (0.63–0.65) | 1.01 (0.99–1.03) | 0.34 (0.33–0.35) | |
| All | 2.88 (2.86–2.91) | 4.79 (4.75–4.83) | 1.20 (1.18–1.22) | 8.56 (8.52–8.60) | 13.67 (13.60–13.74) | 4.35 (4.31–4.38) | |
HNC: head and neck cancer; HPV: human papillomavirus; 95% CI: 95% Confidence Interval.
Rates are per 100,000 and age-adjusted to the 2000 U.S. Standard Population (19 age groups – Census P25-1130).
Confidence intervals (Tiwari model) are 95% for rates.
a
For 1995–2000, SEER Summary Stage 1997 was used; for 2001–2003, SEER Summary Stage 2000 was used; for 2004–2005, Derived SEER Summary Stage 2000 was used.